Targeting the PI3K/Akt/mTOR pathway in hepatocellular carcinoma. - Wikidata - awgldk - TriplyDB

Targeting the PI3K/Akt/mTOR pathway in hepatocellular carcinoma.

Targeting the PI3K/Akt/mTOR pathway in hepatocellular carcinoma.

http://www.wikidata.org/entity/Q34632966

about

Inhibition of Akt/mTOR signaling by the dietary flavonoid fisetin Mechanisms of hepatocellular carcinoma and challenges and opportunities for molecular targeted therapy Targeting p110gamma in gastrointestinal cancers: attack on multiple fronts Genetic alterations in hepatocellular carcinoma: An update MicroRNA-433 inhibits cell proliferation in hepatocellular carcinoma by targeting p21 activated kinase (PAK4)Extract of Pleurotus pulmonarius suppresses liver cancer development and progression through inhibition of VEGF-induced PI3K/AKT signaling pathway Choline plasmalogens isolated from swine liver inhibit hepatoma cell proliferation associated with caveolin-1/Akt signaling Fatty acid esters of phloridzin induce apoptosis of human liver cancer cells through altered gene expression Role of microRNA-21 in radiosensitivity in non-small cell lung cancer cells by targeting PDCD4 gene.Apigenin suppresses GLUT-1 and p-AKT expression to enhance the chemosensitivity to cisplatin of laryngeal carcinoma Hep-2 cells: an in vitro study Leptin signaling molecular actions and drug target in hepatocellular carcinoma Overexpression of GRIM-19, a mitochondrial respiratory chain complex I protein, suppresses hepatocellular carcinoma growth.Synergistic growth inhibition by acyclic retinoid and phosphatidylinositol 3-kinase inhibitor in human hepatoma cells.PIM1 regulates glycolysis and promotes tumor progression in hepatocellular carcinoma Heat Stress-Induced PI3K/mTORC2-Dependent AKT Signaling Is a Central Mediator of Hepatocellular Carcinoma Survival to Thermal Ablation Induced Heat Stress Expression and prognostic significance of contactin 1 in human hepatocellular carcinoma.MiR-21 mediates sorafenib resistance of hepatocellular carcinoma cells by inhibiting autophagy via the PTEN/Akt pathway.Co-activation of AKT and c-Met triggers rapid hepatocellular carcinoma development via the mTORC1/FASN pathway in mice.Effects of maintenance immunosuppression with sirolimus after liver transplant for hepatocellular carcinoma.A PTEN inhibitor displays preclinical activity against hepatocarcinoma cells Blocking autophagic flux enhances matrine-induced apoptosis in human hepatoma cells.The role of Aurora A in hypoxia-inducible factor 1α-promoting malignant phenotypes of hepatocelluar carcinoma.Molecular targeting agents associated with transarterial chemoembolization or radiofrequency ablation in hepatocarcinoma treatment.Chemical inhibition reveals differential requirements of signaling pathways in krasV12- and Myc-induced liver tumors in transgenic zebrafish.Molecular targeted therapy for hepatocellular carcinoma: current and future.Industrial natural product chemistry for drug discovery and development.Hydrodynamic transfection for generation of novel mouse models for liver cancer research.CD147 is increased in HCC cells under starvation and reduces cell death through upregulating p-mTOR in vitro.Targeting multiple oncogenic pathways for the treatment of hepatocellular carcinoma.T-LAK cell-originated protein kinase is essential for the proliferation of hepatocellular carcinoma SMMC-7721 cells.Secretory clusterin contributes to oxaliplatin resistance by activating Akt pathway in hepatocellular carcinoma.Targeting the Ras/Raf/MEK/ERK pathway in hepatocellular carcinoma.SB365 inhibits angiogenesis and induces apoptosis of hepatocellular carcinoma through modulation of PI3K/Akt/mTOR signaling pathway.Characterization of the GNMT-HectH9-PREX2 tripartite relationship in the pathogenesis of hepatocellular carcinoma.Interaction of key pathways in sorafenib-treated hepatocellular carcinoma based on a PCR-array.Upregulation of PI3K/AKT/mTOR, FABP5 and PPARβ/δ in Human Psoriasis and Imiquimod-induced Murine Psoriasiform Dermatitis Model.The role of autophagy in hepatocellular carcinoma: friend or foe.Systematic Analysis of Quantitative Logic Model Ensembles Predicts Drug Combination Effects on Cell Signaling Networks Expression and clinical significance of Nectin-4 in hepatocellular carcinoma Acetylcholine induces fibrogenic effects via M2/M3 acetylcholine receptors in non-alcoholic steatohepatitis and in primary human hepatic stellate cells.

P2860

Q24568189-D23A7BFE-F980-4189-97FA-22A477027FE3 Q26798462-4593B9DC-0345-4BF4-92C9-0B7A672F4D42 Q26823575-818C20B3-244C-4961-B27C-51F52BBB835F Q28073241-5C9B5674-FDFE-48FD-ABAE-B2C763761CA4 Q28251819-67245D42-FCBC-4D47-A54F-6F05D570DFCA Q28481696-D68838DD-108F-42C4-89FD-D266AC3F21CC Q28534403-87A5BF06-F3DB-424A-87C3-C8DBF2723120 Q28543028-9BF24874-E33C-491F-8933-FBB6D6DCA41E Q33618824-B1D0FB22-C1B2-43FB-9EB3-5F5C98A2AE02 Q34029041-E079ED44-C9DD-4281-8209-D88FFF1FE238 Q34548342-DD31EA54-FD7C-4D8E-AD25-E2647EB7BB27 Q34733212-16B195E2-A657-42BC-9AA4-68A20060210A Q35011302-A8899D65-231D-4813-B8E2-EEF5A0206455 Q35793653-A4A239B9-1267-4C00-9C83-8CD9C7230876 Q36128222-DAA6030C-A593-4711-AB95-C2D16800B51F Q36504128-405DF69E-B5EE-40B8-B2F3-EEFCBC7A4D71 Q36557155-7A4B5FC6-5A8F-4E03-96D0-C1CC0F8BADE4 Q36560210-E07C8691-5746-40A0-8DEF-998818C32AA4 Q36840196-C3806B6A-269E-47E3-82E8-96E8C2777723 Q37324522-B073D9F3-1B94-425D-8D31-C81D0637013D Q37420812-C8ED23B0-2C2C-48EE-AB19-0D224EAD7404 Q37505533-C81B4B1D-969F-406E-8851-B04CD327644F Q37581359-BDA75B20-CC5B-4462-A603-03BC486A09B6 Q37738003-31505041-3328-4C8F-AABC-A8CEDC15F3EB Q38151670-A686ED81-A2E9-4D4F-B60F-E8DFFA86B365 Q38154186-45411157-1692-4F49-A974-EB85069904B2 Q38183539-5B8388E7-D9B5-4C70-9E78-CF30ED075B7A Q38825534-3C4A9D87-206A-4B5B-9402-C1B5C0C45BF5 Q38923977-FEFDCDE3-42E0-4C87-B77B-C475AE441BE6 Q39176249-C3D511DC-8847-4333-8048-0CF4CC5C69F7 Q39218247-134BA8B2-34D4-48BB-8E0E-9E775CA7F3D1 Q39270291-6D85646F-A1E4-4DCA-9D06-B47B2C658313 Q39293761-F2E309C3-6B9C-4816-B930-A7C036B2FBAF Q40330584-2693EB96-87A0-497D-B4F7-4262276DA625 Q40928864-F316D460-F120-4E86-8268-407FDE847131 Q41211068-A9D5D046-0F15-4F0A-8BB0-F5A3976D2837 Q41339988-6763643B-FE67-49DB-BEA1-D3783169A0CE Q41582124-1E78F787-C083-48EB-A6D5-78FF3909E61F Q42112265-40652E9F-C0A2-4D27-8133-F3F63284D662 Q42481066-D741A408-5C70-40F8-8032-AF3F8EF2A603

P2860

Targeting the PI3K/Akt/mTOR pathway in hepatocellular carcinoma.

http://www.wikidata.org/entity/Q34632966

description

2011 nî lūn-bûn

@nan

2011 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Targeting the PI3K/Akt/mTOR pathway in hepatocellular carcinoma.

@ast

Targeting the PI3K/Akt/mTOR pathway in hepatocellular carcinoma.

@en

Targeting the PI3K/Akt/mTOR pathway in hepatocellular carcinoma.

@nl

type

label

Targeting the PI3K/Akt/mTOR pathway in hepatocellular carcinoma.

@ast

Targeting the PI3K/Akt/mTOR pathway in hepatocellular carcinoma.

@en

Targeting the PI3K/Akt/mTOR pathway in hepatocellular carcinoma.

@nl

prefLabel

Targeting the PI3K/Akt/mTOR pathway in hepatocellular carcinoma.

@ast

Targeting the PI3K/Akt/mTOR pathway in hepatocellular carcinoma.

@en

Targeting the PI3K/Akt/mTOR pathway in hepatocellular carcinoma.

@nl

P1433

Q34632966-4F2DAFC2-D993-46B2-8728-7C945455AFB4

P1476

Q34632966-8FA4A54E-98AF-4947-8730-E7CE5491335A

P2093

Q34632966-72B214B1-C48A-4A38-9DD1-086C0B7F0A76

P2860

Q34632966-00DAD34A-D100-4E1D-A678-365E894A6A5D

Q34632966-02678511-6A64-4AB4-8395-E6F73D7D4D7A

Q34632966-057802EF-F8F0-4E1B-A916-4FF59AC896B6

Q34632966-068B137B-0E44-4FD5-BE7C-1B51C4CE2EC7

Q34632966-0776447E-6EA0-4E5D-8633-CE152B2411BA

Q34632966-0A6E179C-1081-41CE-89DD-7776D989E42E

Q34632966-0A89D1F0-8347-4222-973C-EAA58D1CCBE1

Q34632966-0BAF5882-6DB3-4CFD-8507-8E8ECE33E4CE

Q34632966-0EE0EAB8-AA9F-4B74-9661-D31FAFF9C9C1

Q34632966-0FE97016-3FB2-4114-A540-05966BB7C8A8

P304

Q34632966-8B578DCC-73DA-4C99-9F11-C7822F19DE39

P31

Q34632966-B6ECCF07-73A2-429D-8122-96498F5FB4FA

P356

Q34632966-2DD59256-283F-4446-8FF4-211E28207A2F

P407

Q34632966-930156D0-2206-4720-8E8A-D250058D55EA

P433

Q34632966-0105CF81-EF12-4684-8B47-9463455EC6C0

P478

Q34632966-5CB6E550-7FC4-4F33-A2C8-098CCA757B23

P50

Q34632966-7A2A5E8B-8ACB-4DB0-9A8F-8F4DC47D7ECF

Q34632966-FE396211-BAB8-49D4-8264-0C8DF20F27FA

P577

Q34632966-5F767782-5F5D-4B95-BE5A-FB345EE7996C

P698

Q34632966-1A32C5CF-1899-42F0-8DD7-97724809F12F

P356

P1433

Future Oncology

P1476

Targeting the PI3K/Akt/mTOR pathway in hepatocellular carcinoma

@en

P2093

Qian Zhou

http://www.w3.org/2001/XMLSchema#string

P2860

Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2

Global cancer statistics

Hepatitis B virus-X protein upregulates the expression of p21waf1/cip1 and prolongs G1-->S transition via a p53-independent pathway in human hepatoma cells

Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex

A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling

Somatic mutations affect key pathways in lung adenocarcinoma

Activation of the N-Ras-PI3K-Akt-mTOR pathway by hepatitis C virus: control of cell survival and viral replication.

Hepatocellular carcinoma: Epidemiology, risk factors and pathogenesis

NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations.

Sorafenib in advanced hepatocellular carcinoma

P304

1149-1167

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2217/FON.11.95

http://www.w3.org/2001/XMLSchema#string

P407

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

7

http://www.w3.org/2001/XMLSchema#string

P50

P577

2011-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21992728

http://www.w3.org/2001/XMLSchema#string